Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia - Concepedia

Concepedia

Publication | Open Access

Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia

DOI Full Paper Access

96

Citations

22

References

2015

Year

David P. Walling, Stephen R. Marder, John M. Kane, W. Wolfgang Fleischhacker, Richard S.E. Keefe, David A. Hosford, Chris Dvergsten, Anthony C. Segreti, Jessica S. Beaver, Steven M. Toler,

Schizophrenia Bulletin

Abstract

These results do not support a benefit of TC-5619 for negative or cognitive symptoms in schizophrenia.

References

	Year	Citations

Page 1